Editor’s Note
Wontech’s Pastelle Pro has received TFDA approval in Taiwan for non-invasive soft tissue procedures and the treatment of pigmented and vascular lesions, marking a significant expansion of the company’s product portfolio in the region.
Laser and energy-based medical solutions company Wontech (CEO Kim Jong-won and Kim Jung-hyun) has expanded its product lineup by obtaining medical device certification for Pastelle Pro in Taiwan.
▲ Wontech
Taiwan’s health authority (TFDA) has approved Pastelle Pro for non-invasive soft tissue procedures including incision, excision, tissue removal, vaporization, coagulation, and hemostasis, as well as treatment of pigmented and vascular lesions, tattoo removal, and hair removal.
The ability to address such a wide range of indications is supported by laser technology operating at two wavelengths: 532nm and 1064nm. Pastelle Pro can be used not only for aesthetic skin treatments but also across various soft tissue procedures. Its specially designed handpiece allows precise control of spot size, depth, and energy density, enabling flexible clinical application for multiple indications.
Taiwan has a vibrant non-invasive aesthetic procedure market, driven by high medical standards and strong demand for medical aesthetics. The growing demand for non-surgical procedures is expected to drive parallel growth in the energy-based medical aesthetic device market, including lasers, RF, and HIFU. Global market research firm Frost & Sullivan estimates Taiwan’s medical aesthetic services market reached approximately USD 2.4 billion in 2025, with a projected CAGR of 9.1% through 2030.
In May, Wontech held its global brand event ‘Wave Taiwan’ in Taiwan, featuring academic lectures and product exhibitions centered on Oligio X, Tightan, Picocare Majesty, and Pico Alex. With the Pastelle Pro approval, the company plans to broaden its product portfolio in Taiwan and accelerate its market penetration.
Reporter Shin Geun-ho ([email protected])